The aim of this study was to investigate the relationship between the detection of micrometastatic cells by immunocytochemistry (ICC) with an anticytokeratin antibody and cytokeratin fragment (CYFRA 21–1) expression detected by an immunofluorescent assay in bone marrow of breast cancer patients. Micrometastatic CK+ cells were screened with a pancytokeratin antibody A45 B/B3 from bone marrow aspiration samples of 102 breast cancer patients (65 primary tumors, 10 local recurrences and 27 distant metastases). CYFRA 21-1 levels were assessed in bone marrow supernatant of these patients before collection of the mononucleated interface cells on a Ficoll-Hypaque density gradient and in 20 control patients. CYFRA 21-1 and CK+ cell detection by ICC were both correlated with clinical stage. CYFRA 21-1 was significantly elevated in patients with micrometastatic disease detected by ICC: 4.77 ng/mL (± 10.87 SD) versus 1.00 ng/mL (± 1.36 SD) in patients with negative ICC (p=0.01). In univariate analysis, a CYFRA 21-1 value ≥1 ng/mL and the presence of CK+ cells were associated with a poorer survival for patients with stage I to III breast cancer (n=65). On multivariate analysis, only pathological nodal status and presence of CK+ cells in bone marrow were independent prognostic factors for overall survival. In conclusion, in this series CYFRA 21-1 was correlated with detection of CK+ cells by ICC in bone marrow, but cannot replace ICC. The presence of CK+ cells in bone marrow remains a strong independent prognostic factor in primary breast cancer.
DielI.J., KaufmannM., CostaS.D.. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.J Natl Cancer Inst1996; 88: 1652–8.
2.
MansiJ.L., GogasH., BlissJ.M., GazetJ.C., BergerU., CoombesR.C.. Outcome of primary-breast-cancer patients with micrometastases: a long- term follow-up study.Lancet1999; 354: 197–202.
3.
FunkeI., SchrautW.. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.J Clin Oncol1998; 16: 557–66.
4.
BraunS., MullerM., HeppF., SchlimokG., RiethmullerG., PantelK.. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.J Natl Cancer Inst1998; 90: 1099–101.
5.
BruggerW., BuhringH.J., GrunebachF.. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells.J Clin Oncol1999; 17: 1535–44.
6.
BraunS., PantelK., MullerP.. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.N Engl J Med2000; 342: 525–33.
7.
GebauerG., FehmT., MerkleE., BeckE.P., LangN., JagerW.. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up.J Clin Oncol2001; 19: 3669–74.
8.
GerberB., KrauseA., MullerH.. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors.J Clin Oncol2001; 19: 960–71.
9.
FrankeW.W., SchillerD.L., MollR.. Diversity of cytokeratins. Differentiation specific expression of cytokeratin polypeptides in epithelial cells and tissues.J Mol Biol1981; 153: 933–59.
10.
MollR., FrankeW.W., SchillerD.L., GeigerB., KreplerR.. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells.Cell1982; 31: 11–24.
11.
MollR., KreplerR., FrankeW.W.. Complex cytokeratin polypeptide patterns observed in certain human carcinomas.Differentiation1983; 23: 256–69.
12.
BaderB.L., MaginT.M., HatzfeldM., FrankeW.W.. Amino acid sequence and gene organization of cytokeratin no. 19, an exceptional tail-less intermediate filament protein.Embo J1986; 5: 1865–75.
13.
BrotherickI., RobsonC.N., BrowellD.A.. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression.Cytometry1998; 32: 301–8.
14.
SladeM.J., SmithB.M., SinnettH.D., CrossN.C., CoombesR.C.. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer.J Clin Oncol1999; 17: 870–9.
15.
StathopoulouA., VlachonikolisI., MavroudisD.. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.J Clin Oncol2002; 20: 3404–12.
16.
XenidisN., VlachonikolisI., MavroudisD.. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.Ann Oncol2003; 14: 849–55.
17.
PujolJ.L., GrenierJ., DauresJ.P., DaverA., PujolH., MichelF.B.. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.Cancer Res1993; 53: 61–6.
18.
YamamotoK., OkaM., HayashiH., TangokuA., GondoT., SuzukiT.. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.Cancer1997; 79: 1647–55.
19.
GoumasP.D., MastronikolisN.S., MastorakouA.N., VassilakosP.J., NikiforidisG.C.. Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma.ORL J Otorhinolaryngol Relat Spec1997; 59: 106–14.
20.
NakataB., OgawaY., IshikawaT.. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.Cancer2000; 89: 1285–90.
21.
International Union Against Cancer.Breast tumours. In: SobinL.H., WittekindC., eds. TNM classification of malignant tumours, 5th edition. New York: John Wiley and Sons, 1997; 123–30.
22.
PiergaJ.Y., BonnetonC., MagdelénatH.. Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer.Br J Cancer2003; 89: 539–45.
23.
BauerK.D., de la Torre-BuenoJ., DielI.J.. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging.Clin Cancer Res2000; 6: 3552–9.
24.
BorgenE., NaumeB., NeslandJ.M.. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells. The European ISHAGE Working Group for Standardization of Tumor Cell Detection.Cytotherapy1999; 1: 377–88.
25.
KuN.O., LiaoJ., OmaryM.B.. Apoptosis generates stable fragments of human type I keratins.J Biol Chem1997; 272: 33197–203.
26.
OmaryM.B., KuN.O., LiaoJ., PriceD.. Keratin modifications and solubility properties in epithelial cells and in vitro.Sub-cell Biochem1998; 31: 105–40.
27.
SheardM.A., VojtesekB., SimickovaM., ValikD.. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21–1) into the extracellular space during apoptosis.J Cell Biochem2002; 85: 670–7.
28.
GionM., BoracchiP., DittadiR.. Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis.Breast Cancer Res Treat2000; 59: 211–21.
29.
BormerO.P.. From tissue polypeptide antigen to specific cytokeratin assays.Tumour Biol1994; 15: 185–7.
30.
PantelK., SchlimokG., BraunS.. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells.J Natl Cancer Inst1993; 85: 1419–24.
31.
MehesG., WittA., KubistaE., AmbrosP.F.. Circulating breast cancer cells are frequently apoptotic.Am J Pathol2001; 159: 17–20.
32.
GionM., PelosoL., MioneR.. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.Cancer J2001; 7: 181–90.
33.
McLaughlinR., McGrathJ., GrimesH., GivenH.F.. The prognostic value of the tumor marker CA 15–3 at initial diagnosis of patients with breast cancer.Int J Biol Markers2000; 15: 340–2.
34.
BastR.C.Jr, RavdinP., HayesD.F.. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.J Clin Oncol2001; 19: 1865–78.
35.
RodriguezC.A., CruzJ.J., MartinT., GomezA., OlaverriA., HernandezM.. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.Cancer2002; 95: 670–1; author reply 671.
36.
GiovanellaL., CerianiL., GiardinaG., BardelliD., TanziF., GaranciniS.. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).Clin Chem Lab Med2002; 40: 298–303.
37.
Hochtlen-VollmarW., GruberR., BodenmullerH.. Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin 19.Int J Cancer1997; 70: 396–400.
38.
RuudP., FodstadO., HovigE.. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells.Int J Cancer1999; 80: 119–25.
39.
KoY., KlinzM., TotzkeG., Gouni-BertholdI., SachinidisA., VetterH.. Limitations of the reverse transcription-polymerase chain reaction method for the detection of carcinoembryonic antigen-positive tumor cells in peripheral blood.Clin Cancer Res1998; 4: 2141–6.
40.
WeigeltB., BosmaA.J., HartA.A., RodenhuisS., van ‘t VeerL.J.. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients.Br J Cancer2003; 88: 1091–4.
41.
IkedaN., MiyoshiY., MotomuraK., InajiH., KoyamaH., NoguchiS.. Prognostic significance of occult bone marrow micrometastases of breast cancer detected by quantitative polymerase chain reaction for cytokeratin 19 mRNA.Jpn J Cancer Res2000; 91: 918–24.
42.
LugoT.G., BraunS., CoteR.J., PantelK., RuschV.. Detection and measurement of occult disease for the prognosis of solid tumors.J Clin Oncol2003; 21: 2609–15.
43.
WiedswangG., BorgenE., KaresenR.. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.J Clin Oncol2003; 21: 3469–78.
44.
NaumeB., BorgenE., NeslandJ.M.. Increased sensitivity for detection of micrometastases in bone- marrow/peripheral-blood stem-cell products from breast cancer patients by negative immunomagnetic separation.Int J Cancer1998; 78: 556–60.
45.
WitzigT.E., BossyB., KimlingerT.. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy.Clin Cancer Res2002; 8: 1085–91.
